The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treat-to-Target Strategy Evaluated for Fibromyalgia Care

Treat-to-Target Strategy Evaluated for Fibromyalgia Care

September 19, 2017 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Treat-to-target is a widely used approach for rheumatoid arthritis, in which rheumatologists prescribe treatments to reach established benchmarks of disease activity.1 Is it time for a similar approach for fibro­myalgia treatment, even though its pathogenesis, disease-activity measures and treatment algorithms are less well understood?

You Might Also Like
  • Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
Explore This Issue
September 2017
Also By This Author
  • FDA Provides 2020 Rheumatology Drug Update

Three fibromyalgia researchers present their case in a new paper, “Treat-to-Target Strategy for Fibromyalgia: Opening the Dialogue.”2 Challenges include validation of existing diagnostic and treatment algorithms, validation of individualized vs. universal treatment strategies and consensus on criteria to assess the effects of treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“A treat-to-target strategy requires very well-defined criteria, but in fibromyalgia, these are not definite,” says Mary-Ann Fitzcharles, MB, ChB, professor of medicine at McGill University Health Centre in Montreal, Quebec, Canada. Her co-authors are Winfried Hauser, MD, medical director, Psychosomatic Clinic of Internal Medicine at Klinikum Saarbrücken in Saarbrücken, Germany, and Daniel J. Clauw, MD, director of the Chronic Pain and Fatigue Research Center at the University of Michigan Medical School in Ann Arbor, Mich.

The ACR endorsed preliminary diagnostic criteria for fibromyalgia, which were first published in 2010 and modified in 2011, but there are no established benchmarks for disease activity.3,4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Why We Need Treat to Target

Fibromyalgia is a prevalent disease affecting about 2% of the global population. Its often long-lasting symptoms affect quality of life and function, and it may impact both direct and indirect health costs.5-7 “About 20–30% of patients with defined inflam­matory joint disease also have underlying fibromyalgia as an important component,” says Dr. Fitzcharles.

Development of a treat-to-target strategy should include clear disease definition, knowledge of long-term consequences of inadequate treatment, effects of and duration of treatment, defined meaningful outcome measures and accepted response criteria, say the authors. Fibromyalgia’s pathogenesis and disease mechanisms are still not well understood, and precise diagnosis may be elusive and delay treatment, says Dr. Fitzcharles. “You have to be sure you have a well-defined condition and must have universally accepted diagnostic criteria,” says Dr. Fitzcharles. Some fibromyalgia experts debate the ACR-endorsed criteria, possibly because widespread pain, the hallmark symptom, may vary greatly in intensity over time and be highly variable between patients.8 Patients may express somatic symptoms and mood issues very differently, making them hard to measure among a larger population.9

In fibromyalgia, weighting each patient’s symptoms may reflect global health status more effectively than using generic measurements, the authors say.10

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We need international acceptance of the diagnostic criteria for this condition. We need to know who we are treating,” says Dr. Fitzcharles. “We need long-term epidemiological studies to give us a good idea of what happens to these patients and a clearer understanding of patient outcomes.”

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Soft Tissue Pain Tagged With: ACR Journal Review, American College of Rheumatology, criteria, Fibromyalgia, Pain, Research, rheumatology, Strategy, TreatmentIssue: September 2017

You Might Also Like:
  • Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Audioconference: Management of Fibromyalgia

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.